The Heterozygous familial hypercholesterolemia (heFH) drugs in development market research report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Heterozygous familial hypercholesterolemia (heFH). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued products.
GlobalData tracks 25 drugs in development for Heterozygous familial hypercholesterolemia (heFH) by 22 companies/universities/institutes. The top development phase for Heterozygous familial hypercholesterolemia (heFH) is phase iii with seven drugs in that stage. The Heterozygous familial hypercholesterolemia (heFH) pipeline has 25 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Heterozygous familial hypercholesterolemia (heFH) pipeline products market are: CRISPR Therapeutics, Verve Therapeutics and NewAmsterdam Pharma Company.
The key targets in the Heterozygous familial hypercholesterolemia (heFH) pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin Related Protein 3, and Apolipoprotein B.
The key mechanisms of action in the Heterozygous familial hypercholesterolemia (heFH) pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor with 13 drugs in Pre-Registration. The Heterozygous familial hypercholesterolemia (heFH) pipeline products include four routes of administration with the top ROA being Subcutaneous and six key molecule types in the Heterozygous familial hypercholesterolemia (heFH) pipeline products market including Gene Therapy, and Monoclonal Antibody.
Heterozygous familial hypercholesterolemia (heFH) overview
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused by getting a mutation of the FH gene from an affected parent. Symptoms include xanthesmas, corneal arcus, aortic rupture, and peripheral vascular disease. Risk factors include age, sex, smoking, and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or type III dyslipoproteinemia.
For a complete picture of Heterozygous familial hypercholesterolemia (heFH)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
